Rhumbline Advisers Buys 7,408 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Rhumbline Advisers grew its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 4.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 180,964 shares of the company’s stock after purchasing an additional 7,408 shares during the quarter. Rhumbline Advisers’ holdings in Xeris Biopharma were worth $613,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Xeris Biopharma during the third quarter worth $35,000. R Squared Ltd bought a new stake in Xeris Biopharma during the fourth quarter valued at $42,000. Quantbot Technologies LP acquired a new stake in Xeris Biopharma during the 3rd quarter worth about $44,000. Janney Montgomery Scott LLC grew its holdings in Xeris Biopharma by 31.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock worth $78,000 after acquiring an additional 5,500 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Xeris Biopharma by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock worth $107,000 after acquiring an additional 2,954 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on XERS shares. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday. Jefferies Financial Group restated a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $4.24 on Friday. The business has a 50-day simple moving average of $3.55 and a 200 day simple moving average of $3.24. Xeris Biopharma Holdings, Inc. has a one year low of $1.69 and a one year high of $4.50. The firm has a market capitalization of $632.10 million, a price-to-earnings ratio of -9.42 and a beta of 2.32.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.